The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).
 
Renata Ferrarotto
Consulting or Advisory Role - Ayala Pharmaceuticals; Bicara Therapeutics; Elevar Therapeutics; G1 Therapeutics; Guidepoint Global; Intellisphere; Merck Serono; Prelude Therapeutics; Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst)
 
Diana Bell
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Kaiyi Li
No Relationships to Disclose
 
Frank Mott
No Relationships to Disclose
 
George R. Blumenschein
Employment - Janssen (I); johnon & Johnson (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo, INC; Genentech; Gilead Sciences; Instil Bio; Janssen Oncology; Johnson & Johnson (I); Lilly; Maverick Therapeutics; MedImmune; Merck; Novartis; Novartis; Roche; Tyme; Virogin Biotech; Xcovery
Research Funding - Adaptimmune; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Daiichi Sankyo INC; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Merck; Novartis; Regeneron; Repertoire Immune Medicines; Roche; Tmunity Therapeutics, Inc.; Torque; Verastem; Xcovery
 
Luana Guimaraes de Sousa
No Relationships to Disclose
 
Mehmet Altan
Consulting or Advisory Role - AstraZeneca; BMS; GlaxoSmithKline
Speakers' Bureau - Nektar
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Shattuck Labs (Inst)
Travel, Accommodations, Expenses - Nektar
 
Mario L. Marques-Piubelli
No Relationships to Disclose
 
Eduardo Andreazza Dal Lago
No Relationships to Disclose
 
Diana Kaya
No Relationships to Disclose
 
Myrna Godoy
No Relationships to Disclose
 
Michael Elliot Kupferman
Stock and Other Ownership Interests - Abbvie; Intersect ENT
 
Bonnie S. Glisson
Research Funding - CUE Biopharma (Inst); ISA Pharmaceuticals (Inst); Medimmune (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; ISA Pharmaceuticals
 
Adel K. El-Naggar
No Relationships to Disclose
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Lilly; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly